New cocktail of drugs aims to shrink Hard-to-Treat abdominal tumors

NCT ID NCT07268677

Not yet recruiting Disease control Sponsor: Guoxiang Cai Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether adding pirfenidone and sintilimab to standard chemotherapy can shrink tumors in 30 people with colorectal cancer that has spread to the lining of the abdomen. Participants will receive the drug combination before any other treatment. The study will first check if enough tumors respond; if too few do, the trial will stop early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pirfenidone, sintilimab, oxaliplatin, capecitabine
What this could lead to: If this combination works, it could offer a new treatment option for people with colorectal cancer that has spread to the lining of the abdomen, potentially shrinking tumors before surgery.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug combination may cause side effects, and there is no guarantee it will be more effective than standard chemotherapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm peritoneal carcinomatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.